Compare WH & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WH | ADPT |
|---|---|---|
| Founded | 2017 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 4.5B |
| IPO Year | 2017 | 2019 |
| Metric | WH | ADPT |
|---|---|---|
| Price | $71.59 | $29.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $97.59 | $28.31 |
| AVG Volume (30 Days) | 1.2M | ★ 2.3M |
| Earning Date | 10-21-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | N/A | ★ 63.89 |
| EPS | ★ 2.16 | N/A |
| Revenue | ★ $1,429,000,000.00 | $276,976,000.00 |
| Revenue This Year | $3.29 | $5.94 |
| Revenue Next Year | $6.25 | $22.42 |
| P/E Ratio | $33.10 | ★ N/A |
| Revenue Growth | 1.49 | ★ 54.77 |
| 52 Week Low | $66.87 | $12.00 |
| 52 Week High | $90.35 | $29.96 |
| Indicator | WH | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | 64.69 |
| Support Level | $71.55 | $15.47 |
| Resistance Level | $78.18 | $29.96 |
| Average True Range (ATR) | 2.01 | 1.39 |
| MACD | 0.61 | 0.05 |
| Stochastic Oscillator | 77.85 | 97.72 |
As of Dec. 31, 2025, Wyndham Hotels & Resorts operates 869,000 rooms across more than 20 brands predominantly in the economy and midscale segments. Ramada is the largest brand, representing around 14% of all rooms, with Days Inn (13%) and Super 8 (10%) the next two largest brands, as of the end of 2025. During the past several years, the company has expanded its extended stay/lifestyle brands, which appeal to travelers seeking to experience the local culture of a given location. The company closed its La Quinta acquisition in the second quarter of 2018, adding around 90,000 rooms at the time the deal closed. Wyndham launched a new extended stay economy scale segment concept, ECHO, in the spring of 2022. The United States represented 58% of total rooms in 2025.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.